ACNE

DOI: 10.7241/ourd.2022book.2_1

First Page (Prima pagina)

I. PREVALEN?A

Acneea este o afec?iune inflamatorie cronică a foliculului pilo-sebaceu. Leziunile elementare din acnee sunt hiperseboreea, leziunile reten?ionale ?i leziunile inflamatorii
(papule, pustule, noduli).

Hiperseborea este responsabilă de un aspect lucios al pielii, în absen?a transpira?iei; se localizează la nivel medio-facial (frunte, nas, obraji, regiunea mentonieră.

Leziunile retent?ionale sunt reprezentate de comedoane.

COMEDON= PUNCT NEGRU= COMEDON DESCHIS este o leziune caracteristică acneei, indiferent de vârstă; apare datorită obstruc?iei orificiului infundibular cu keratină ?i sebum.

MICROCHIST= PUNCT ALB= COMEDON ÎNCHIS este o papula? de 2-3 mm, de culoa-rea pielii, fermă, determinată de acumularea de sebum ?i keratină într-un infundibul închis; uneori se simte la palpare. Poate evolua spre ruptură la exterior sau în derm.

Manifestările clinice din acnee sunt determinate de un mecanism patogenic complex, în care sunt implica?i, în mod special, următorii factori: glanda sebacee, epiteliul canalului infundibular ?i Cutibacterium acnes [1].

Keywords

  • acne; comedoane; ACNEE NEONATALĂ; ACNEE INFANTILĂ; ACNEE PRE?COLARĂ; ACNEE PREPUBERTARĂ; ACNEEA ADOLESCENTULUI; ACNEE CONGLOBATA; ACNEE FULMINANS; Benzoil peroxid; Retinoizi topici; Tetracicline; Isotretinoin

References

1. Ouedraogo AN, Kabre Ouedraogo SSS, Ouedraogo MS, et al. [Acne: prevalence, perceptions and beliefs among pupils and students in Ouagadougou, Burkina Faso]. Our Dermatol Online. 2017;8:10-6.
2. Zouboulis C C. Acne and sebaceous gland function. Clin Dermatol. 2004;22:360-6.
3. Akdogan N, Dogan S, Atakan N, et al. Association of serum hormone levels with acne vulgaris: Low estradiol level can be a pathogenetic factor in female acne. Our Dermatol Online. 2018;9:249-56.
4. Zouboulis CC, Chen W, Thornton M, et al. Sexual hormones in human skin. Horm Metab Res. 2007;39:85-95.
5. Zouboulis CC, Jourdan E, Picardo M. Acne is an inflammatory disease and alterations of sebum composition initiate acne lesions. J Eur Acad Dermatol Venereol. 2014;28:527-32.
6. Beylot C, Auffret N, Poli F, et al. Propionibacterium acnes: an update on its role in the pathogenesis of acne. J Eur Acad Dermatol Venereol. 2014;28:271-8.
7. Eichenfield LF, Krakowski AC, Piggott C, et al; American Acne and Rosacea Society. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. Pediatrics. 2013;131 Suppl 3:S163-86.
8. Mancini AJ. Acne in childhood: an update. Pediatr Ann. 2013;42:418-27.
9. Senhaji G, El Jouari O, Elloudi S, et al. Acne fulminans: a rare form of acne. Our Dermatol Online. 2019;10:91-2.
10. Piotrkowicz M, Wasyłyszyn T, Borowska K. Unusual acne conglobata case mimicking cervicofacial actinomycosis: A case report with literature review. Our Dermatol Online. 2017;8:460-62.
11. Dreno B, Poli F, Pawin H, et al. Development and evaluation of a Global Acne Severity Scale (GEA Scale) suitable for France and Europe. J Eur Acad Dermatol Venereol. 2011;25:43-8.
12. Gold LS, Dhawan S, Weiss J, J Am Acad Dermatol. 2019;80:168-77.
13. Dreno B, Thiboutot D, Gollnick H, et al; Global Alliance to Improve Outcomes in Acne. Antibiotic stewardship in dermatology: limiting antibiotic use in acne. Eur J Dermatol. 2014;24:330-4.
14. Kolli SS, Pecone D, Pona A, et al. Topical Retinoids in Acne Vulgaris: A Systematic Review. Am J Clin Dermatol. 2019;20:345-65.
15. Tan J, Tanghetti E, Baldwin H, et al. The Role of Topical Retinoids in Prevention and Treatment of Atrophic Acne Scarring: Understanding the Importance of Early Effective Treatment. J Drugs Dermatol. 2019;18:255-60.

16. Tan J, Thiboutot D, Popp G, et al. Randomized phase3 evaluation of trifarotene 50?g/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80:1691-9.
17. Tanghetti EA, Werschler WP, Lain T, et al. Tazarotene 0.045% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Results from Two Phase 3 Trials. J Drugs Dermatol. 2020;19:70-7.
18. Marahatta S, Shrestha U. Hospital prevalence and causes of non-adherence to acne treatment: A report from Nepal. Our Dermatol Online. 2021;12:251-6.
19. Yale S, Stefanko N, McCarthy P, et al. Severe methemoglobinemia due to topical dapsone misuse in a teenage girl. Pediatr Dermatol. 2020;37:377-8.
20. Tanghetti E, Harper J, Baldwin H, et al Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females. J Drugs Dermatol. 2018;17:1192-8.
21. Moore A, Ling M, Bucko A, et al. Efficacy and Safety of Subantimicrobial Dose, Modified-Release Doxycycline 40 mg Versus Doxycycline 100 mg Versus Placebo for the treatment of Inflammatory Lesions in Moderate and Severe Acne: A Randomized, Double-Blinded, Controlled Study. J Drugs Dermatol. 2015;14:581-6.
22. Sanjel K, Zhang XM. Progress of different treatment modalities to limit the use of antibiotics in the treatment of acne. Our Dermatol Online. 2022;13:92-7.
23. Moore A, Green LJ, Bruce S, et al. Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials. J Drugs Dermatol. 2018;17:987-96.
24. Nguyen TA, Krakowski AC. The ?Heart Sign?: An Early Indicator of Dose-Dependent Doxycycline-Induced Phototoxicity. Pediatr Dermatol. 2016;33:e69-71.
25. Hellmann-Regen J, Herzog I, Fischer N, et al. Do tetracyclines and erythromycin exert anti-acne effects by inhibition of P450-mediated degradation of retinoic acid?. Exp Dermatol. 2014;23:290-3.
26. Traitement de l?acné par voie locale et générale (recommandations). 2015. http://www.sfdermato.org/media/pdf/recommandation/algorithme- 54ac60356d1b9584a71ccaac92cf3724.pdf
27. Miller IM, Echeverri?a B, Torrelo A, et al. Infantile acne treated with oral isotretinoin. Pediatr Dermatol. 2013;30:513-8.
28. Dreno B, Blouin E. Acne, pregnant women and zinc salts: a literature review. Ann Dermatol Venereol. 2008;135:27-33.
29. Roberts E, Nowsheen S, Davis D, et al. Use of spironolactone to treat acne in adolescent females. Pediatric Dermatol. 2020;00:1-5.
30. Kręgiel M, Żuchowska A, Tomaszewska K, et al. Acne fulminans in the course of oral isotretinoin treatment. Presentation of cases. Our Dermatol Online. 2017;8:210-4.
31. Incel Uysal P. Rapid-onset oral isotretinoin-induced acne fulminans without systemic symptoms in a male adolescent. Our Dermatol Online. 2021;12:417-8.

Comments are closed.